Product Images Fintepla

The text is indicating a chart or table that shows the proportion of patients and percentage reduction from baseline in convulsive seizure frequency. No further information is available from the given text.*

Description: This is a medication package that includes one bottle of FINTEPLA Oral Solution with a concentration of 2.2 mg/mL, as well as two oral syringes.*

This text is a product description for two sets of oral syringes. The first set contains two syringes with a capacity of 3mL each and dose markings in 0.1 mL increments. The second set contains two syringes with 6mL capacity each and dose markings in 0.5 mL increments. These syringes seem to be designed for measuring and administering medication orally.*

This text is describing the parts of a syringe which include the tip, barrel, base, and plunger.*

This is a description of a 3 mL syringe that has dose markings in 0.1 mL increments. The text does not provide any further information.*

This text indicates that the 6 mL syringe has dose markings in increments of 0.5 mL. It does not give any additional context or information.*

This is a medication called Fmtepla which contains fenfluramine in an oral solution. The NDC code is 43376-322-30 and each bottle contains 30mL of liquid with a concentration of 2.2 mg/mL. It is only for oral use and should be stored at a controlled room temperature between 68°F to 77°F (20°C to 25°C). The pharmacist must dispense the enclosed medication guide to each patient. The unused portion of the bottle should be discarded 3 months after first opening. The medication is recommended by Zogenix Inc. in Emeryville, CA. The recommended dosage should be consulted with the prescribing information.*

This is a description of Finteplar (fenfluramine) as an oral solution with a concentration of 2.2 mg/mL. It is recommended to see the prescribing information for the dosage. The medication guide should be given to each patient, and the drug should be stored at a controlled room temperature between 68°F and 77°F (20°C to 25°C). The contents include one 30 mL bottle, and the unused portion should be discarded after 3 months from the first opening.*

This is a medication labeled with the NDC code 43376-322-36. It is an oral solution with a concentration of 2.2 mg/mL, and it is stored at controlled room temperature. The medication is only for oral use and should be used as directed, with the recommended dosage being provided in the prescribing information. The pharmacist is instructed to dispense a medication guide to each patient. The medication should not be refrigerated or frozen and any unused portion should be discarded 3 months after first opening.*

Fintepla is an oral solution medication containing 2.2 mg/mL of fenfluramine and is intended for oral use. It is recommended to see the prescribing information for the recommended dosage. Each medication guide should be dispensed to patients, and the contents of one 360 ml bottle should be used. The medication should be stored at a controlled temperature of 68°F to 77°F (20°C to 25°C) and not refrigerated or frozen. The unused portion should be discarded within three months after the first opening, as stated in the NDC 43376-322-36.*

The document appears to be a graph representing the percentage reduction from baseline in drop seizure frequency in patients. The graph compares the effects of three different drugs: placebo, BFINTEPLA 0.2 mg/kg/day, and WFINTEPLA 0.7 mg/kg/day. The x-axis of the graph represents the different percentage ranges of reduction, while the y-axis represents the different drugs. It appears that both BFINTEPLA and WFINTEPLA have a significantly greater effect on reducing drop seizure frequency than placebo.*